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Background: The performance of comorbidity measures for predicting mortality in chronic disease populations
and using ICD-9 diagnosis codes in administrative health data has been investigated in several studies, but less is
known about predictive performance with ICD-10 data and for other health outcomes. This study investigated
predictive performance of five comorbidity measures for population-based diabetes cohorts in administrative data.
The objectives were to evaluate performance for: (a) disease-specific and general health outcomes, (b) data based
on the ICD-9 and ICD-10 diagnoses, and (c) different age groups.
Methods: Performance was investigated for heart attack, stroke, amputation, renal disease, hospitalization, and death in
all-age and age-specific cohorts. Hospital records, physician billing claims, and prescription drug records from one
Canadian province were used to identify diabetes cohorts and measure comorbidity. The data were analysed using
multiple logistic regression models and summarized using measures of discrimination, accuracy, and fit.
Results: In Cohort 1 (n = 29,058), for which only ICD-9 diagnoses were recorded in administrative data, the Elixhauser
index showed good or excellent prediction for amputation, renal disease, and death and performed better than the
Charlson index. Number of diagnoses was a good predictor of hospitalization. Similar results were obtained for Cohort
2 (n = 41,925), in which both ICD-9 and ICD-10 diagnoses were recorded in administrative data, although predictive
performance was sometimes higher. For age-specific models of mortality, the Elixhauser index resulted in the largest
improvement in predictive performance in all but the youngest age group.
Conclusions: Cohort age and the health outcome under investigation, but not the diagnosis coding system, may
influence the predictive performance of comorbidity measure for studies about diabetes populations using
administrative health data.
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Administrative health data are frequently used for surveil-
lance and research in chronic disease populations. These
data contain medical records generated for management
and remuneration purposes at the time of hospital dis-
charge or provision of services [1]. Besides providing
timely and cost-effective information, their popularity
stems from the fact that they are population-based and
capture both utilization and diagnostic information. How-
ever, to obtain unbiased conclusions from observational
chronic disease studies using administrative data requires* Correspondence: lisa.lix@med.umanitoba.ca
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reproduction in any medium, provided the orcontrol of confounding factors that may differ among pop-
ulations and are associated with the health utilization or
outcome measure under investigation. Demographic and
socioeconomic variables are included as risk-adjustment
measures in most observational studies. Comorbid condi-
tions, pre-existing conditions that co-occur with the index
disease, [2] are also commonly considered.
A number of comorbidity measures are available for
administrative health data. These include both general-
purpose and disease-specific comorbidity measures; [3,4]
general-purpose measures are advantageous because
they can be used to compare comorbidity characteristics
across different chronic disease populations. Some gen-
eral measures are based on simple counts of the number
of diagnoses or prescription drugs for an individual [5].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prescription drug codes. The Chronic Disease Score
(CDS), for example, is based on a set of codes for pre-
scription drugs used to treat major chronic conditions
[6]. Diagnosis-related measures, such as the Charlson
and Elixhauser indices, use International Classification
of Disease (ICD) diagnosis codes to identify major
comorbid conditions [7,8]. Both the Charlson and
Elixhauser indices were originally used to predict mor-
tality for in-hospital populations, but they have also been
applied to outpatient populations and to some other
health outcomes [9-11]. The Elixhauser index was devel-
oped using the clinical modification of the 9th revision of
ICD (i.e., ICD-9-CM); the Charlson index was also pro-
posed using this classification system. However, many
countries, including Canada, Australia, New Zealand,
Japan, China, and some European countries have now
implemented the 10th revision of ICD (i.e., ICD-10),
which covers a broader range of clinical information.
Quan et al. [12] extended the Charlson and Elixhauser
indices to ICD-10 codes, but only a few studies have
compared the predictive performance of comorbidity
algorithms based on ICD-9 and ICD-10 codes. Li et al.
[13] observed good predictive performance for in-hospital
mortality using both the Charlson and Elixhauser
indices with the two coding systems in Canadian data.
Sundararajan et al. [14] found similar results using
Australian data and when the outcome was in-hospital
mortality. However, the authors noted that predictive
performance for other outcomes could be investigated.
Several studies have used administrative data to study
health outcomes and healthcare use in diabetes popula-
tions. Diabetes places a significant burden on the health
care system [15-18], and therefore is of great interest to
clinicians and policy analysts. It is responsible for vascular
and neurologic complications such as acute myocardial in-
farction (AMI), stroke, lower extremity amputation (LEA),
end stage renal disease (ESRD), and retinopathy [15-20].
De Berardis et al. found that the hospitalization rate in dia-
betics is twice that of the general population, accounting
for an excess of 12,000 hospital admissions per 100,000
person years [15]. Studies that have investigated comorbid-
ity measures in diabetes populations using administrative
data have been limited, although Quail et al. [21] found
that the predictive performance of different comorbidity
measures for mortality and hospitalization outcomes was
variable in study cohorts with diabetes.
Only a few studies have compared the predictive per-
formance of comorbidity measures in different age groups,
although these groups may differ in their comorbidity char-
acteristics. Studies that have investigated risk-adjustment
tools have often focused on older populations [3,22,23]. In
contrast, Quail et al. compared an age-inclusive cohort (i.e.,
20+ years) to an age-restricted cohort (i.e., 65+ years) andfound diminished performance of comorbidity measures in
predicting mortality and hospitalization in the latter [21].
Given this background, the study purpose was to
investigate predictive performance of comorbidity mea-
sures in diabetes cohorts defined from administrative
health data. The objectives were to compare performance
for: (a) disease-specific and general health outcomes,
(b) data based on ICD-9 and ICD-10 diagnoses, and
(c) different age groups.
Methods
Data sources
Study data were from the Canadian province of Saskatch-
ewan, which has a population of approximately 1.1 million
according to the 2006 national census. About 40 per cent
of residents live in one of two major urban centres, while
the remainder of residents live in rural communities [24].
Like other Canadian provinces and territories,
Saskatchewan has a universal health care system. All
hospital records and virtually all physician billing claims
and outpatient prescription drug records are captured
for residents eligible to receive health insurance benefits.
Records of hospital, physician, and prescription drug
services are collected in electronic databases that can
be anonymously linked, via a unique personal health
number, to the population health insurance registration
file [25]. The registration file captures dates of health
insurance coverage, demographic characteristics and
location of residence.
A hospital record is completed upon patient discharge.
Diagnoses are recorded using ICD-9 up to and including
the 2000/01 fiscal year (a fiscal year extends from April 1
to March 31). Beginning in 2001/02, ICD-10-CA diagno-
ses were used. Between three and 16 diagnoses are cap-
tured in the data prior to the introduction of ICD-10-CA
and up to 25 diagnoses are captured subsequently.
Physicians paid on a fee-for-service basis submit billing
claims to the ministry of health for payment purposes. A
single diagnosis is recorded on each claim using three-
digit ICD-9 codes.
Prescription drug files contain records of outpatient
drugs dispensed to residents eligible for coverage. Regis-
tered Indians, who represent about 9 per cent of the
population, have their prescription drug benefits paid by
the federal government rather than the province so their
records are not available in the provincial database. Pre-
scription drug records include the date of dispensation
and national drug identification number (DIN). DINs
are linked to codes in the American Hospital Formulary
System (AHFS) Pharmacologic-Therapeutic Classifica-
tion System (www.ashp.org). The AHFS is used to group
drugs with similar pharmacologic, therapeutic, and/or
chemical characteristics using a hierarchical system with
four levels.
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administrative data for research has been documented in
multiple studies [26-28]. Ethics approval for this re-
search was received from the University of Saskatchewan
Biomedical Research Ethics Board. Data were accessed
and analysed at the Health Quality Council in accordance
with a standing data sharing agreement between that
organization and the provincial health ministry.
Study cohorts
To permit comparisons of ICD coding systems, two cohorts
were defined using the diabetes case definition developed
by the National Diabetes Surveillance System, [29] which
has been validated in previous research [30,31]. This case
definition identifies all individuals with a diabetes diagnosis
(ICD-9 250; ICD-10-CA E10-E14) in at least one hospital
record or two physician claims within a two-year period.
The diagnosis index date is the date of hospitalization or
the date of the last of the two physician visits.
Cohort 1 was composed of residents aged 20 years and
over at their diagnosis index date who satisfied the dia-
betes case definition and had uninterrupted health cover-
age from 1997/98 to 1999/00 or until death. The ICD-9
coding system was exclusively used during this period to
record diagnoses in both hospital and physician databases.
Cohort 2 was composed of residents aged 20 years and
over at their diabetes index date who satisfied the diabetes
case definition and had uninterrupted health coverage
from 2001/02 to 2003/04 or until death. ICD-9 (for phys-
ician data) and ICD-10 (for hospital data) coding systems
were in use during this latter period. Data from fiscal year
1996/97 onward, the first year of available data, were used
to ascertain diabetes cases.
Comorbidity measures
Five measures were investigated (Table 1): number of
different diagnoses, Charlson index, Elixhauser index,Table 1 Description of comorbidity measures
Measure Definition Data So
Number of
diagnoses
Identifies number of diagnosis codes,
to the third digit. Minimum score
is 0 and there is no maximum
Hospital
billing cl
Charlson index Summarizes diagnoses for 17 conditions.
Total score can range from 0 to 32
Hospital
billing cl
Elixhauser index Captures diagnoses for 31 conditions.
No total score is produced
Hospital
billing cl
Number of drugs Identifies number of prescription drugs
using six-digit AHFS codes. Total score




Uses AHFS codes to identify number of
different prescriptions for treating 17
conditions. Total score can range from 0 to 35
Prescript
aVariable categories were defined based on previous research and by examining th
the categories were created to minimize sparse cell sizes, AHFS American Hospital Fnumber of different drugs, and CDS. For Cohort 1, data
from 1997/98 were used to define each measure while
for Cohort 2, data were from 2001/02.
The number of different diagnoses in hospital and
physician data [32] was based on codes recorded to the
third digit in both ICD-9 (e.g., 812) and ICD-10 (e.g., S42).
Diagnoses related to pregnancy, childbirth, or abortions
were excluded. The Charlson index was originally developed
using data abstracted from hospital charts, [7] subsequently
adapted to hospital data coded with ICD-9, and then
extended to data coded with ICD-10 [12]. The index is
based on diagnoses for 17 conditions; each condition is
assigned a weight from one to six. A summary score is com-
puted ranging from 0 to 32, where a higher score indicates
greater comorbidity. In accordance with previous research,
[33] the Charlson index was computed using diagnosis
codes in both hospital and physician data. For hospital data,
only those conditions present on admission were included.
The Elixhauser index [8] has also been extended from its
original formulation using ICD-9 to ICD-10 [12]. Each of
the 31 conditions comprising the index is coded as a binary
indicator. This index was also implemented using diagnosis
codes from both hospital and physician data. The number
of different prescription drugs has also been shown to be a
valid measure of comorbidity [11]. This measure was based
on six-digit AHFS codes, of which there are 125. The CDS
[6] was originally developed for predicting mortality and
hospitalization outcomes. It uses the first four digits of
AHFS codes to identify prescription drugs for treating 17
conditions. Each disease treatment group is assigned a
weight and the weighted category scores are used to pro-
duce a single summary score from 0 to 35, where a high
score indicates greater comorbidity.
Outcome variables
Study outcomes were identified using data from the two
years following the comorbidity measurement year ofurce Variable Categories for the Predictive Modela
records and physician
aims
0−2 (reference), 3–5, 6–9, 10 or more
records and physician
aims
0−1 (reference), 2–3, 4–5, 6 or more
records and physician
aims
Dummy variables (0 = absent; 1 = present)
are used to define the 31 conditions
ion drug records 0−1 (reference), 2–3, 4–5, 6 or more
ion drug records 0−1 (reference), 2–3, 4–5, 6–7, 8 or more
e frequency distributions for each of the comorbidity measures. Cut-points for
ormulary System.
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to 1999/00 for Cohort 1 and 2002/03 to 2003/04 for
Cohort 2. Outcomes of AMI, stroke, LEA, and ESRD were
based on previously-defined algorithms [34-36]. Specific-
ally, AMI cases were identified with an ICD-9 code of 410
or ICD-10 code of I21 in the most responsible (i.e., pri-
mary) diagnosis field in hospital records. AMI hospitaliza-
tions that occurred within a one-year period following a
previous AMI were excluded, to ensure that only incident
cases were captured. Stroke cases were identified using
ICD-9 codes 430, 431, 434, 436, and 362.3 and ICD-10
codes I60, I61, I63, I64, and H34.1 in the most responsible
diagnosis field in hospital records. The LEA case definition
was based on procedure codes in hospital records. It cap-
tured both minor (toes, forefoot, foot below ankle), and
major (ankle, below knee, above knee) amputation proce-
dures not related to trauma or malignancy. Individuals
with ESRD were identified from service codes for
chronic dialysis and renal transplantation. The full list
of procedure and service codes for LEA and ESRD is
available from the authors.
Other outcomes that were investigated included death,
hospitalization for any reason, and hospitalization for
diabetes (ICD-9 250; ICD-10-CA E10-E14). Deaths were
identified from the population registry. Hospitalizations
associated with pregnancy, childbirth, or abortions were
excluded. Transfers between facilities and hospital re-
admissions within 24 hours of discharge were considered
part of the initial hospital admission [35].
Other study variables
The cohorts were described on age, sex, recent diabetes
diagnosis, region of residence, and income quintile. Age
and sex were defined from the population registration file.
Individuals who had a diagnosis index date in 1997/98 or
2001/02 for Cohorts 1 and 2, respectively, were identified
as recently diagnosed. Individuals with a prior index date
were defined as previously diagnosed. Urban and rural re-
gion of residence was defined based on postal code in the
registration file; urban residents were those living in the
health regions of Saskatoon and Regina.
Income quintile was defined using a method based on
average household income from the 2001 Statistics
Canada Census [37]. Each individual’s postal code was
assigned to a dissemination area (DA), the smallest geo-
graphic unit for which Census data are reported. Income
ranges were determined such that the entire Saskatch-
ewan population was divided into five approximately
equal groups. Residents were assigned an income quin-
tile according to their DA average household income.
Some residents could not be assigned a quintile because
income measures are suppressed for some DAs, usually
because of small population size. Approximately 14 per
cent of the total population had a missing incomequintile. A method was used that first developed a predictive
model for the missing quintiles based on socio-demographic
variables that are generally not suppressed, including marital
status, ethnicity, and unemployment. A multiple imputation
approach was then used to assign income quintile, taking
the average of the multiple imputed values, [38] for all DAs
that did not have missing information on one or more
of these socio-demographic variables and for all indi-
viduals who did not have a missing postal code. Aver-
age total income, reported by Statistics Canada in
2001, was $12,700 for the lowest quintile, $29,700 for
the second quintile, $47,200 for the third quintile,
$71,800 for the fourth quintile, and $128,700 for the
highest quintile (http://www5.statcan.gc.ca/cansim).
Statistical analysis
Frequencies, means, and standard deviations were used to
describe the cohorts’ characteristics. Performance of each
comorbidity measure was assessed using multiple logistic
regression by fitting base and full models to the data [32].
For each cohort, the base model contained the following
variables: age (centred on the mean), a quadratic age term,
sex, region of residence (urban [reference], rural), income
quintile (Q1/Q2, Q3 [reference], Q4/Q5), and recent dia-
betes diagnosis (prior [reference], recent). The full model
contained all variables in the base model in addition to a
comorbidity variable(s), which were modelled as categor-
ical variables. The variable categorization adopted for each
comorbidity measure is provided in Table 1.
The base and full models were compared using the
c-statistic, a measure of discrimination that is equivalent
to the area under the receiver operating characteristic
curve for dichotomous outcomes [39,40]. The c-statistic
ranges from zero to one, with a value of one representing
perfect prediction and a value of 0.5 representing chance
prediction. A value between 0.7 and 0.8 is considered to
demonstrate acceptable predictive performance, while a
value greater than 0.8 demonstrates excellent predictive
performance. The 95% confidence intervals (CIs) were
computed. The difference in c-statistics for the base and
full models (i.e., Δc) was tested for statistical significance
using the method of DeLong et al. [41]. The percentage
change in the c-statistic between base and full models was
also computed.
To investigate model fit, a likelihood ratio test (LRT)
was also conducted for the base and full models [42].
The LRT statistic asymptotically follows a χ2 distribution,
with the degrees of freedom (df ) for this statistic equal
to the difference in df for the base and full models. A
statistically significant LRT statistic indicates that the
inclusion of the comorbidity measure results in an im-
provement in model fit. Each test was conducted at the
α = .01 significance level, to reduce the overall probabil-
ity of a Type I error.
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calibration (i.e., accuracy) and discrimination, was also com-
puted. The Brier score ranges from zero to one, [43] with
lower values indicating less prediction error. Given that a
score of 0.25 can be achieved by assigning an event probabil-
ity of 0.5 to each individual, [43] a value less than 0.25 was
considered to represent acceptable prediction error.
All analyses were conducted using SAS software [44].
Separate analyses were conducted for Cohorts 1 and 2
and for age-specific groups within each cohort. The age-
specific groups were: 20 to 44 years, 45 to 64 years, 65
to 74 years and 75+ years.
Results and discussion
Cohort 1 consisted of a total of 29,058 individuals and Co-











Age, mean (SD) 36.2 (6.3) 55.5 (5.6) 69.5 (2.8) 80.6 (4.6) 62.5
Female 52.1 44.1 46.0 53.5
Urban 58.3 53.0 48.7 46.3
Missing <0.1 0.2 0.1 <0.1
Income Quintile
Q1 (lowest) 32.7 26.1 25.8 27.1
Q2 22.0 23.2 23.2 24.7
Q3 15.4 16.2 17.1 19.1
Q4 13.5 14.8 15.1 12.8
Q5 (highest) 15.4 18.2 17.4 15.1
Missing 0.9 1.5 1.5 1.1
Recent diagnosis 27.5 24.3 21.7 21.3
Outcomes (%)c
AMI 0.5 1.6 2.9 3.3
Stroke 0.3 1.0 2.7 3.7
LEA 0.3 0.8 1.2 1.3
ESRD 0.7 0.5 0.4 0.2
Mortality 0.9 4.0 10.0 22.0
Hosp., any 34.3 43.7 57.6 64.7
Hosp., diabetes 18.6 21.3 26.6 30.2
Comorbidity summary measures, mean (SD)
# diagnoses 6.0 (4.8) 6.2 (4.8) 6.7 (4.7) 7.4 (4.8) 6.6
Charlson score 0.4 (0.8) 0.6 (1.2) 0.9 (1.5) 1.2 (1.7) 0.8
# drugs 3.1 (3.2) 4.2 (3.5) 5.3 (3.6) 5.9 (3.8) 4.7
CDS 2.5 (3.1) 3.9 (3.5) 5.0 (3.6) 5.3 (3.6) 4.3
aCohort 1 was defined using administrative data from fiscal years 1996/97 to 1997/
reported are percentages unless otherwise indicated; cOutcomes were defined over
AMI Acute Myocardial Infarction; LEA Lower Extremity Amputation; ESRD End-Stageindividuals were excluded from Cohort 1 because they did
not have health insurance coverage throughout the study
observation period; this percentage was similar for Cohort
2 (3.9%). Table 2 describes the age-specific demographic,
health outcome, and comorbidity characteristics for both
cohorts. The youngest age group was more likely to be
comprised of urban residents while the oldest age group
was more likely to contain rural residents. In Cohort 1,
close to one-third of individuals in the youngest age group
were in the lowest income quintile, compared to 27.1% of
individuals in the 75+ age group. Similar results were ob-
served for Cohort 2. Overall, individuals in Cohort 1 were
more likely to have a recent diabetes diagnosis compared
to Cohort 2. The overall percentage of individuals experi-
encing each health outcome was higher in Cohort 1 than










(15.0) 36.8 (5.8) 55.3 (5.6) 69.6 (2.9) 81.0 (4.8) 62.4 (15.0)
47.9 52.3 43.9 44.9 54.5 47.8
51.0 55.6 53.4 51.1 47.8 51.8
0.1 0.1 0.2 0.1 <0.1 0.1
27.1 32.5 25.7 24.4 25.0 26.1
23.4 23.2 22.1 23.4 23.8 23.0
17.0 14.4 16.4 17.5 19.1 17.0
14.2 13.0 15.1 15.4 14.6 14.8
16.9 16.0 19.5 18.0 16.4 17.9
1.3 1.0 1.3 1.4 1.2 1.2
23.4 16.0 12.6 9.6 8.3 11.3
2.2 0.4 0.9 1.9 3.0 1.6
2.0 0.2 0.7 1.8 2.9 1.4
1.0 0.3 0.9 0.9 0.6 0.8
0.4 0.3 0.5 0.5 0.3 0.4
9.4 1.2 3.0 8.4 21.5 8.4
51.0 31.7 40.9 55.2 61.8 48.1
24.4 14.5 16.8 22.0 24.0 19.5
(4.8) 6.2 (5.7) 6.8 (6.0) 7.9 (6.6) 8.9 (6.8) 7.5 (6.4)
(1.4) 0.4 (0.8) 0.6 (1.2) 1.0 (1.7) 1.3 (1.9) 0.8 (1.5)
(3.7) 3.1 (3.3) 4.5 (3.7) 5.9 (3.8) 6.4 (4.0) 5.1 (3.9)
(3.6) 2.8 (3.4) 4.4 (3.8) 5.6 (3.7) 5.7 (3.7) 4.8 (3.8)
98 and Cohort 2 was defined using data from 1996/97 to 2001/02; bNumbers
a two-year observation period, SD Standard Deviation, Hosp Hospitalization,
Renal Disease, CDS Chronic Disease Score.






Hypertension- uncomplicated 33.3 42.7
Diabetes- uncomplicated 14.7 14.7
Chronic pulmonary disease 13.9 13.5
Congestive heart failure 8.0 8.0
Depression 5.8 6.0
Solid tumors 5.0 5.4
Diabetes- complicated 3.2 3.0
Psychiatric 2.4 2.7
Cardiac arrhythmias 2.3 2.8
Fluid and electrolyte disorders 1.9 2.7
RA/collagen vascular disease 1.9 1.9
Renal failure 1.8 3.1
Valvular disease 1.5 2.2
Peripheral vascular disease 1.4 1.5
Metastatic cancer 1.3 1.7
Other neurological disorders 1.1 1.2
Coagulopathy 1.0 2.5
Hypertension- complicated 0.7 1.0
Pulmonary circulatory disorders 0.7 0.8
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and CDS, but not the Charlson index score, for which both
cohorts had the same mean score. As expected, the average
scores for the comorbidity measures increased with age.
Tables 3 and 4 describe the comorbidities comprising
the Charlson and Elixhauser indices, respectively. For the
Charlson index, the most common comorbidities in both
cohorts were uncomplicated diabetes and chronic pul-
monary disease. For the Elixhauser index, the most com-
mon comorbidities, in addition to uncomplicated diabetes,
were uncomplicated hypertension and chronic pulmonary
disease. More than 60% of individuals in both Cohorts 1
and 2 had at least one of the Elixhauser comorbidities.
Table 5 reports the modelling results for both cohorts
when age-inclusive analyses were conducted. The LRTs
were statistically significant for all comorbidity measures
and for all outcomes, except for the CDS for AMI and the
Elixhauser index for stroke in Cohort 2. These results indi-
cate that the comorbidity measures almost always resulted
in an improvement in model fit. Therefore, the focus of
the remainder of this section is on the c-statistics and
Brier scores.
For AMI, the base models had c-statistics of 0.66 (95%
CI: 0.64, 0.68) and 0.68 (95% CI: 0.66, 0.70) in Cohorts 1
and 2, respectively and both had a Brier score of 0.02,
indicating poor predictive performance and low error.Table 3 Charlson index comorbidities (%) for study
cohorts
Comorbidity Cohort 1a
(n = 29,058 )
Cohort 2
(n = 41,925)
Diabetes, without complications 15.5 15.3
Chronic pulmonary disease 14.0 13.7
Congestive heart failure 8.0 8.1
Cancer 5.5 5.8
Cerebrovascular disease 5.5 4.7
Myocardial infarction 2.5 3.0
Diabetes, with complications 2.3 2.5
Peptic ulcer disease 2.0 1.7
Renal disease 1.9 3.2
Peripheral vascular disease 1.4 1.6
Metastatic carcinoma 1.3 1.8
Connective tissue disease 0.8 0.8
Dementia 0.8 0.9
Mild liver disease 0.6 0.6
Paraplegia and hemiplegia 0.6 0.4
Moderate or severe liver disease 0.1 0.2
AIDS/HIV <0.1 <0.1
1 or more Charlson comorbidities 39.1 37.2
aCharlson index comorbidities were defined using administrative data from
fiscal year 1997/98 for Cohort 1 and 2001/02 for Cohort 2.
Liver disease 0.6 0.7
Obesity 0.6 1.0
Paraplegia 0.6 0.4
Deficiency anemia 0.5 0.8
Alcohol abuse 0.4 0.7
Hypothyroidism 0.4 1.1
Drug abuse 0.3 0.4
Peptic ulcer disease 0.3 0.4
Lymphoma 0.2 0.2
Weight loss 0.1 0.2
AIDS <0.1 <0.1
Blood loss anemia 0.0 <0.1
1 or more Elixhauser comorbidities 61.4 65.5
aComorbidities were defined using data from fiscal year 1997/98 for Cohort 1
and 2001/02 for Cohort 2.The addition of a comorbidity measure was associated
with, at most, a 2.95% increase in the c-statistic. None of
the full models had c-statistics that exceeded 0.70.
The base model for stroke in Cohort 1 had a c-statistic
of 0.70 (95% CI: 0.68, 0.72) and a Brier score of 0.02, in-
dicating good discrimination and low error. The im-
provement in the c-statistic was only statistically
significant for the Elixhauser index (2.56%). The c-statis-
tic for the base model in Cohort 2 was similar but the
Table 5 Model comparisons for health outcomes in all-age diabetes cohorts
Cohort 1a (n = 29,058) Cohort 2 (n = 41,925)
Model (df)b c-statisticc (95% CI) Δcd (%) Brier score LRTe c-statisticc (95% CI) Δc (%) Brier score LRTe
AMI
Base (7) 0.66 (0.64, 0.68) . 0.02 . 0.68 (0.66, 0.70) . 0.02 .
# diagnoses (10) 0.67 (0.65, 0.69) 0.01 (1.37) 0.02 21.1* 0.68 (0.67, 0.71)* <0.01 (1.47) 0.02 32.1*
Charlson (10) 0.67 (0.65, 0.69) 0.01 (1.52) 0.02 21.5* 0.69 (0.67, 0.71)* 0.01 (1.92) 0.02 37.3*
Elixhauser (35) 0.68 (0.66, 0.69)* 0.02 (2.43) 0.02 44.2* 0.70 (0.68, 0.72)* 0.02 (2.95) 0.02 62.5*
# drugs (10) 0.68 (0.66, 0.69)* 0.02 (2.43) 0.02 36.0* 0.68 (0.66, 0.70) <0.01 (0.88) 0.02 24.1*
CDS (11) 0.67 (0.65, 0.69)* 0.01 (2.28) 0.02 32.8* 0.68 (0.66, 0.70) <0.01 (0.29) 0.02 6.1
Stroke
Base (7) 0.70 (0.68, 0.72) . 0.02 . 0.71 (0.69, 0.72) . 0.01 .
# diagnoses (10) 0.71 (0.70, 0.73) 0.01 (1.57) 0.02 37.8* 0.71 (0.69, 0.73) <0.01 (0.85) 0.01 18.9*
Charlson (10) 0.72 (0.70, 0.73) 0.02 (1.85) 0.02 44.3* 0.71 (0.69, 0.73) <0.01 (0.85) 0.01 17.2*
Elixhauser (35) 0.72 (0.70, 0.74)* 0.02 (2.56) 0.02 45.4* 0.71 (0.69, 0.73) <0.01 (0.85) 0.01 20.6
# drugs (10) 0.71 (0.69, 0.73) 0.01 (0.85) 0.02 19.5* 0.71 (0.70, 0.73) <0.01 (0.99) 0.01 24.2*
CDS (11) 0.71 (0.69, 0.73) 0.01 (1.28) 0.02 33.7* 0.71 (0.70, 0.73) <0.01 (0.99) 0.01 21.2*
LEA
Base (7) 0.65 (0.62, 0.68) . 0.01 . 0.68 (0.65, 0.70) . 0.01 .
# diagnoses (10) 0.71 (0.69, 0.74)* 0.06 (10.36) 0.01 77.4* 0.74 (0.72, 0.77)* 0.06 (9.75) 0.01 128.7*
Charlson (10) 0.74 (0.71, 0.77)* 0.09 (14.06) 0.01 128.4* 0.76 (0.74, 0.79)* 0.08 (12.70) 0.01 201.7*
Elixhauser (35) 0.78 (0.75, 0.81)* 0.13 (20.71) 0.01 305.6* 0.79 (0.76, 0.82)* 0.11 (16.69) 0.01 372.8*
# drugs (10) 0.70 (0.67, 0.72)* 0.05 (7.42) 0.01 53.0* 0.74 (0.72, 0.76)* 0.06 (9.31) 0.01 110.2*
CDS (11) 0.69 (0.66, 0.72)* 0.04 (6.34) 0.01 42.4* 0.72 (0.70, 0.75)* 0.04 (6.65) 0.01 74.5*
ESRD
Base (7) 0.67 (0.63, 0.72) . <0.01 . 0.65 (0.61, 0.69) . <0.01 .
# diagnoses (10) 0.74 (0.70, 0.79)* 0.07 (10.73) <0.01 49.0* 0.77 (0.73, 0.80)* 0.12 (18.52) <0.01 128.0*
Charlson (10) 0.80 (0.76, 0.84)* 0.13 (19.08) <0.01 138.6* 0.82 (0.79, 0.86)* 0.17 (27.01) <0.01 276.6*
Elixhauser (35) 0.84 (0.80, 0.89)* 0.17 (25.78) <0.01 328.6* 0.87 (0.84, 0.90)* 0.22 (34.41) <0.01 555.1*
# drugs (10) 0.73 (0.69, 0.76)* 0.06 (8.20) <0.01 36.6* 0.71 (0.68, 0.75)* 0.06 (9.88) <0.01 50.2*
CDS (11) 0.75 (0.71, 0.79)* 0.08 (12.07) <0.01 61.3* 0.72 (0.68, 0.76)* 0.07 (11.11) <0.01 55.3*
Hospitalization, any reason
Base (7) 0.63 (0.62, 0.64) . 0.24 . 0.63 (0.62, 0.63) . 0.24 .
# diagnoses (10) 0.70 (0.69, 0.71)* 0.07 (11.13) 0.22 2115.1* 0.70 (0.69, 0.70)* 0.07 (11.31) 0.22 3101.3*
Charlson (10) 0.68 (0.67, 0.69)* 0.05 (8.11) 0.23 1424.1* 0.67 (0.67, 0.68)* 0.04 (7.32) 0.23 1794.8*
Elixhauser (35) 0.69 (0.68, 0.69)* 0.06 (9.06) 0.22 1663.7* 0.68 (0.68, 0.69)* 0.05 (8.60) 0.23 2165.5*
# drugs (10) 0.66 (0.66, 0.67)* 0.03 (5.09) 0.23 823.1* 0.65 (0.65, 0.66)* 0.02 (3.98) 0.23 996.2*
CDS (11) 0.65 (0.64, 0.66)* 0.02 (3.50) 0.23 539.2* 0.64 (0.64, 0.65)* 0.01 (2.23) 0.24 503.0*
Hospitalization, diabetes
Base (7) 0.60 (0.59, 0.61) . 0.18 . 0.59 (0.59, 0.60) . 0.15 .
# diagnoses (10) 0.65 (0.65, 0.66)* 0.05 (8.65) 0.18 889.9* 0.66 (0.65, 0.66)* 0.07 (10.83) 0.15 1251.0*
Charlson (10) 0.66 (0.65, 0.67)* 0.06 (9.65) 0.17 1194.1* 0.65 (0.64, 0.66)* 0.06 (9.98) 0.15 1141.8*
Elixhauser (35) 0.67 (0.66, 0.68)* 0.07 (11.65) 0.17 1554.3* 0.66 (0.66, 0.67)* 0.07 (12.35) 0.15 1715.9*
# drugs (10) 0.64 (0.63, 0.64)* 0.04 (5.66) 0.18 524.5* 0.63 (0.62, 0.63)* 0.04 (6.09) 0.15 633.9*
CDS (11) 0.63 (0.62, 0.63)* 0.03 (4.16) 0.18 365.1* 0.62 (0.61, 0.63)* 0.03 (4.57) 0.15 397.7*
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Table 5 Model comparisons for health outcomes in all-age diabetes cohorts (Continued)
Death
Base (7) 0.77 (0.76, 0.78) . 0.08 . 0.79 (0.78, 0.79) . 0.07 .
# diagnoses (10) 0.79 (0.78, 0.80)* 0.02 (3.39) 0.08 499.4* 0.80 (0.80, 0.81)* 0.01 (2.16) 0.07 475.1*
Charlson (10) 0.82 (0.81, 0.82)* 0.05 (6.53) 0.07 1014.0* 0.82 (0.82, 0.83)* 0.03 (4.57) 0.07 1018.0*
Elixhauser (35) 0.83 (0.82, 0.83)* 0.06 (7.96) 0.07 1379.9* 0.84 (0.83, 0.84)* 0.05 (6.10) 0.06 1618.7*
# drugs (10) 0.79 (0.78, 0.80)* 0.02 (2.74) 0.08 429.1* 0.80 (0.79, 0.81)* 0.01 (1.78) 0.07 401.4*
CDS (11) 0.78 (0.77, 0.79)* 0.01 (1.96) 0.08 306.1* 0.79 (0.79, 0.80)* <0.01 (0.89) 0.07 216.9*
aCohort 1 was defined using administrative data from fiscal years 1996/97 to 1997/98 and Cohort 2 was defined using data from 1996/97 to 2001/02; bBase model
includes covariates of age, age2, sex, income quintile, geography, and recent diabetes diagnosis, and full models include these variables in addition to the
specified comorbidity measure; cA c-statistic with * is significantly different (p < .01) from the c-statistic for the base model, dΔc = c-statistic for full model minus
c-statistic for base model, eA likelihood ratio test (LRT) with * is statistically significant at α = .01; df=degrees of freedom, CDS Chronic Disease Score, AMI Acute
Myocardial Infarction, LEA Lower Extremity Amputation, ESRD End-Stage Renal Disease.
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significant for any of the full models.
For LEA, the c-statistic for the base model in Cohort 1
was below 0.70; each comorbidity measure resulted in a
statistically significant increase in the c-statistic. The lar-
gest improvement was for the Elixhauser index (20.71%),
followed by the Charlson index (14.06%). Both indices
had low Brier scores (0.01). Similar results were found
for Cohort 2, although the c-statistics were higher for
the full models, and the change in the c-statistics was,
overall, smaller than for Cohort 1.
Similar findings were observed for ESRD. In Cohort 1,
there was excellent discrimination for the full model
containing the Elixhauser index (c = 0.84; 95% CI: 0.80,
0.89). In Cohort 2, both the Elixhauser index (c = 0.87;
95% CI: 0.84, 0.90) and Charlson index (c = 0.82; 95%
CI: 0.79, 0.86) resulted in full models with excellent pre-
dictive performance.
The base models for the two hospitalization outcomes
had lower c-statistics and higher Brier scores than the
base models for disease-specific outcomes. While all of
the comorbidity measures resulted in statistically signifi-
cant improvements in the c-statistic, none of the full
models had values greater than 0.70. For hospitalization
for any reason, the largest improvement was observed
for the number of different diagnoses. For diabetes
hospitalization, the largest improvement was observed
for the Elixhauser index, but it was similar to the value
for the number of diagnoses.
For death, the c-statistic of the base model for Cohort
1 was 0.77 (95% CI: 0.76, 0.78) and the Brier score was
0.08, indicating good discrimination and low prediction
error. Results were similar for Cohort 2. All comorbidity
measures were associated with statistically significant in-
creases in the c-statistic. In Cohort 1, the largest increase
was for the Elixhauser index (c = 0.83; 95% CI: 0.82,
0.83) followed by the Charlson index (c = 0.82; 95% CI:
0.81, 0.82). Similar results were found for Cohort 2,
although the percentage change in the c-statistics were
smaller than for Cohort 1.The age-specific results are reported in Table 6. We
conducted the analyses for death only, to limit the num-
ber of model comparisons and also because for some
outcomes, age-specific models could not be fit to the
data given the low numbers of health events. LRT statis-
tics for all models were statistically significant, except
for the model for number of drugs in the 20 to 44 age
group in Cohort 1.
For each age group, the base model c-statistic was con-
sistently below 0.70. Brier scores were smallest for the
youngest age group and largest for the oldest age group.
For Cohort 1 in the youngest age group, only the Charlson
index resulted in a significant increase in the c-statistic. In
Cohort 2 in the youngest age group, the Charlson index,
number of different diagnoses, Elixhauser index and num-
ber of different prescription drugs resulted in statistically
significant increases in the c-statistic. The results for the
other age groups were similar in the two cohorts. The
addition of each comorbidity measure to the base model
was associated with a statistically significant increase in
the c-statistic. The Elixhauser index consistently resulted
in the largest increase in the c-statistic, followed by the
Charlson index.
Conclusions
This study of comorbidity measures in population-based
cohorts with diagnosed diabetes had the following key
findings. First, there were substantial differences in the
predictive performance of the base set of risk-adjustment
variables selected for this study. Performance was lowest
for hospitalization measures and highest for death and
stroke. Improvements in model fit were often observed
when a comorbidity measure was included in the model.
However, for the health outcomes of AMI and stroke,
there was limited utility associated with the inclusion of a
comorbidity measure in the risk-adjustment model, based
on model discrimination (i.e., c- statistic). For the other
health outcomes, there was always a statistically significant
improvement in the c-statistic for the full models. ESRD
and death were the outcomes for which the comorbidity
Table 6 Model comparisons for death in age-specific diabetes cohorts
Cohort 1a (n = 29,058) Cohort 2 (n = 41,925)
Model (df)b c-statisticc (95% CI) Δcd (%) Brier score LRTf c-statisticc (95% CI) Δc (%) Brier score LRTf
20-44 years
Base (7) 0.65 (0.56, 0.74) . 0.01 . 0.64 (0.57, 0.71) . 0.01 .
# diagnoses (10) 0.74 (0.65, 0.83) 0.09 (13.02) 0.01 14.1* 0.75 (0.69, 0.81)* 0.11 (16.82) 0.01 43.1*
Charlson (10) 0.81 (0.74, 0.89)* 0.16 (24.20) 0.01 50.1* 0.80 (0.74, 0.86)* 0.16 (24.61) 0.01 87.9*
Elixhausere – – – – 0.72 (0.66, 0.79)* 0.08 (12.77) 0.01 36.2*
# drugs (10) 0.72 (0.64, 0.80) 0.07 (10.26) 0.01 9.0 0.71 (0.65, 0.78)* 0.07 (11.06) 0.01 21.1*
CDS – – – – 0.70 (0.63, 0.77) 0.06 (9.35) 0.01 19.0*
45-64 years
Base (7) 0.62 (0.59, 0.65) . 0.04 . 0.62 (0.59, 0.64) . 0.03 .
# diagnoses (10) 0.72 (0.69, 0.74)* 0.10 (15.81) 0.04 149.0* 0.69 (0.67, 0.72)* 0.07 (12.85) 0.03 149.0*
Charlson (10) 0.76 (0.74, 0.79)* 0.14 (22.74) 0.04 345.0* 0.74 (0.72, 0.76)* 0.12 (20.33) 0.03 368.2*
Elixhauser (35) 0.77 (0.74, 0.79)* 0.15 (23.71) 0.04 416.7* 0.75 (0.73, 0.77)* 0.13 (21.95) 0.03 416.7*
# drugs (10) 0.60 (0.66, 0.71)* 0.08 (10.97) 0.04 103.5* 0.68 (0.65, 0.70)* 0.06 (9.76) 0.03 103.5*
CDS (11) 0.66 (0.63, 0.69) * 0.04 (6.29) 0.04 60.1* 0.65 (0.62, 0.68)* 0.03 (5.69) 0.03 60.1*
65-74 years
Base (7) 0.60 (0.58, 0.62) . 0.09 . 0.59 (0.57, 0.61) . 0.08 .
# diagnoses (10) 0.68 (0.66, 0.70)* 0.08 (13.88) 0.09 186.8* 0.66 (0.64, 0.68)* 0.07 (12.05) 0.08 186.8*
Charlson (10) 0.73 (0.71, 0.75)* 0.13 (22.24) 0.08 407.0* 0.71 (0.69, 0.73)* 0.12 (20.03) 0.07 407.0*
Elixhauser (35) 0.75 (0.73, 0.76)* 0.15 (24.58) 0.08 548.8* 0.72 (0.70, 0.74)* 0.13 (22.24) 0.07 548.8*
# drugs (10) 0.67 (0.65, 0.69)* 0.07 (11.71) 0.09 131.1* 0.65 (0.63, 0.67)* 0.06 (9.68) 0.08 131.1*
CDS (11) 0.66 (0.64, 0.68)* 0.06 (9.70) 0.09 63.0* 0.62 (0.60, 0.64)* 0.03 (4.92) 0.08 63.0*
75+ years
Base (7) 0.64 (0.62, 0.66) . 0.16 . 0.67 (0.65, 0.68) . 0.16 .
# diagnoses (10) 0.67 (0.66, 0.69)* 0.03 (4.84) 0.16 159.7* 0.69 (0.68, 0.70)* 0.02 (3.60) 0.16 159.7*
Charlson (10) 0.70 (0.68, 0.71)* 0.06 (8.91) 0.16 315.3* 0.71 (0.70, 0.72)* 0.04 (6.76) 0.15 318.0*
Elixhauser (35) 0.72 (0.70, 0.73)* 0.08 (12.34) 0.15 633.5* 0.74 (0.73, 0.75)* 0.07 (11.11) 0.15 633.5*
# drugs (10) 0.68 (0.66, 0.69)* 0.04 (5.47) 0.16 161.2* 0.69 (0.68, 0.70)* 0.02 (3.45) 0.16 161.2*
CDS (11) 0.67 (0.65, 0.68)* 0.03 (4.22) 0.16 95.1* 0.68 (0.67, 0.69)* 0.01 (1.95) 0.16 95.1*
aCohort 1 was defined using data from fiscal years 1996/97 to 1997/98 and Cohort 2 was defined using data from 1996/97 to 2001/02; bBase model includes age,
age2, sex, income quintile, geography, and recent diabetes diagnosis, and full models include these variables in addition to the specified comorbidity measure; cA
c-statistic with * is significantly different (p < .01) from the c-statistic for the base model; dΔc = c-statistic for full model minus c-statistic for base model; eSome
full models failed to converge due to the small number of deaths; fA likelihood ratio test (LRT) with * is statistically significant at α = .01; df=degrees of freedom;
CDS Chronic Disease Score.
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ive performance. The model containing the Elixhauser
index had the best predictive performance for all out-
comes except for hospitalization for any reason, where
number of diagnoses performed well. However, this was
not always the case when age-specific cohorts were inves-
tigated. Similar changes in the c-statistics were observed
for the diagnosis-based comorbidity measures regardless
of whether the measures were based on ICD-9 codes only,
or both ICD-9 and ICD-10 codes. The comorbidity mea-
sures based on prescription drugs had similar changes in
the c-statistic values in the two cohorts to those observed
using the diagnosis-based measures. Overall, however,comorbidity measures based on diagnosis codes per-
formed better than comorbidity measures based on pre-
scription drug codes.
The findings that the Charlson and Elixhauser indices
performed well for predicting general measures of hospital
utilization and mortality concurs with previous research
[10,45,46]. However, this research has also shown that pre-
dictive performance of these comorbidity measures tends
to be lower for healthcare utilization than for mortality, but
still greater than when the predictive model is limited to
socio-demographic variables and recency of diagnosis.
Farley et al. [45] found that for predicting healthcare expen-
ditures in the general population, simple count measures,
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performed better than the Charlson and Elixhauser indices,
which is consistent with most of the findings of the current
study.
Schneeweiss et al. [47] observed that in a population of
older adults, comorbidity measures based on medication
codes had poorer performance than measures based on
diagnosis codes. We also observed this for the age-specific
analyses. The percentage change in the c-statistic for the full
models containing the CDS and number of different drugs
was larger in younger than in older age groups. The poor
performance of measures based on prescription drug codes
may arise because we focused on short-term outcomes and
some drugs are used by individuals primarily for preventive
therapy, as opposed to being used for treatment of chronic
conditions. Finally, the addition of new drug classes to the
marketplace since the CDS was originally developed may
also contribute to its poorer predictive performance.
An interesting finding was that members of Cohort 1
had fewer comorbid conditions but were more likely to
experience a health outcome compared to members of
Cohort 2, who had a greater burden of comorbidity but
were less likely to experience a health outcome. This
observation of greater comorbidity could potentially be
explained by the increase in the number of diagnostic
fields from three in 1997/98 to 25 in 2001/02 in hospital
administrative data. However, this does not appear to
have affected the overall predictive performance of the
comorbidity measures. The finding that predictive per-
formance of comorbidity measures was not substantially
different when diagnoses were based on ICD-9 only
compared to when they were based on both ICD-9 and
ICD-10 is consistent with previous research [12,13].
There are some limitations to this study. Comorbidity
was defined using only a single year of data and was
based on data from the year immediately prior to the
outcome observation period. However, this methodology
parallels one adopted in a similar study involving a gen-
eral elderly population [10]. Moreover, previous research
found that varying the time frame for measurement of
comorbidity had a trivial effect on predictive perform-
ance [48,49]. The study cohorts were not independent;
80% of the individuals in Cohort 1 were also present in
Cohort 2. It would have been preferable to examine pre-
dictive performance in independent cohorts defined over
the same period of time, with different ICD coding sys-
tems being used in parallel, to avoid the potential
confounding effects of cohort aging and changes in ICD
coding on predictive performance. Sundarajan et al. [14]
also noted the potential for temporal confounding in
their investigation of changes in ICD coding. However, a
study design that used independent cohorts was not pos-
sible to implement to evaluate the potential effects of
the change in diagnosis coding. We observed that theprevalence of comorbid conditions was similar in both co-
horts, with the exception of uncomplicated hypertension,
suggesting little change in capture of major comorbidities
with a change in diagnosis coding. Other comorbidity mea-
sures could have been included in the analysis. For example,
an updated version of the CDS has been developed, [50]
although Schneeweiss et al. [47] found that this revision did
not result in improved predictive performance when com-
pared to the original CDS in an elderly population. Another
limitation is that some of the investigated outcomes were
sparse in the cohorts, which can reduce the power of
Delong’s [41] test for differences in discriminative perform-
ance of the models [51]. Finally, it is generally recognized
that when working with administrative data, misclassifica-
tion may arise due to inaccuracies in the assignment of
diagnostic codes [32]. For example, rule-out diagnoses,
which are used to indicate that an individual does not have
a condition, may be incorrectly classified as comorbidities.
Major strengths of this study are the investigation of
multiple outcome measures, several commonly-used
general measures of comorbidity and measures based on
both diagnosis and prescription drug codes. As well, we
conducted age-specific analyses as well as analyses for
all-ages cohorts to assess the generalizability of perform-
ance of comorbidity measures across the population.
Using population-based data as opposed to data for a
specific clinical cohort improves generalizability of the
study results. Finally, our base model included a variety
of variables that can be validly defined using administra-
tive data and a broad range of potential risk variables.
In summary, our study suggests that the predictive per-
formance of comorbidity measures based on administra-
tive health data in population-based diabetes cohorts will
vary with the outcome measure under investigation,
although the Elixhauser index performed well overall. Pre-
dictive performance of all measures may not be equivalent
for all age groups. At the same time, changes in the diag-
nosis coding system used in hospitalization data do not
appear to affect predictive performance over time.
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